(thirdQuint)Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas.

 Subjects are patients with glioblastoma (GBM), anaplastic astrocytoma (AA) or grade 3 or greater WHO astrocytic, oligodendroglial or mixed glial tumors, which were initially diagnosed by histologic examination of biopsy/resection.

 Modified classical "3+3" phase I design used to determine maximum tolerated dose of topotecan in combination with Temodar.

.

 Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas@highlight

Objectives: - To determine the maximum tolerated dose of oral topotecan when administered with Temodar to patients with malignant glioma - To characterize any toxicity associated with the combination oral topotecan and Temodar.

 - To observe patients for clinical antitumor response when treated with oral topotecan and Temodar.

